Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
57.30
-1.70 (-2.88%)
Apr 17, 2026, 2:32 PM HKT
HKG:2315 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,585 | 403.85 | 417.66 | 626.62 | 466.45 |
Short-Term Investments | - | - | 7.89 | 9.15 | 106.98 |
Trading Asset Securities | - | - | 8.49 | 8.2 | - |
Cash & Short-Term Investments | 1,585 | 403.85 | 434.04 | 643.97 | 573.42 |
Cash Growth | 292.51% | -6.96% | -32.60% | 12.30% | -40.11% |
Accounts Receivable | 300.31 | 229.61 | 142.38 | 107.68 | 103.09 |
Other Receivables | 17.58 | 6.93 | 6.04 | 4.17 | 14.96 |
Receivables | 317.89 | 236.54 | 148.43 | 111.85 | 118.05 |
Inventory | 169.87 | 110.48 | 9.9 | 23.73 | 21.65 |
Other Current Assets | 75.87 | 65.66 | 130.69 | 139.74 | 161.11 |
Total Current Assets | 2,149 | 816.53 | 723.05 | 919.3 | 874.24 |
Property, Plant & Equipment | 1,237 | 1,213 | 1,451 | 1,599 | 1,391 |
Long-Term Investments | 192.06 | 222.61 | 241.24 | 250.81 | 9.69 |
Other Intangible Assets | 52.7 | 61.14 | 28.13 | 30.65 | 6.06 |
Long-Term Deferred Tax Assets | 0.99 | 0.96 | - | - | - |
Long-Term Deferred Charges | 74.92 | 96.35 | - | - | - |
Other Long-Term Assets | 18.36 | 5.23 | 6.16 | - | 21.86 |
Total Assets | 3,724 | 2,415 | 2,449 | 2,800 | 2,303 |
Accounts Payable | 135.83 | 115.48 | 175.23 | 146.19 | 102.44 |
Accrued Expenses | 99.34 | 38.06 | 27.89 | 51.62 | 53.66 |
Short-Term Debt | 153.38 | 181.04 | - | - | - |
Current Portion of Long-Term Debt | 36.22 | 17.58 | 176.84 | 126.67 | - |
Current Portion of Leases | 31.94 | 17.86 | 26.36 | 44.94 | 26.9 |
Current Income Taxes Payable | 2 | 4.01 | 4.51 | 4.2 | 5.02 |
Current Unearned Revenue | 103.76 | 102.19 | 69.22 | 56.38 | 61.58 |
Other Current Liabilities | 367.83 | 58.69 | 97.56 | 176.06 | 196.96 |
Total Current Liabilities | 930.3 | 534.91 | 577.62 | 606.05 | 446.56 |
Long-Term Debt | 179.88 | 156.13 | 173.91 | 52.17 | - |
Long-Term Leases | 182.67 | 197.67 | 167.01 | 191.51 | 62.9 |
Long-Term Unearned Revenue | 82.54 | 84.9 | 87.07 | 89.93 | 92.8 |
Long-Term Deferred Tax Liabilities | - | - | 1.9 | - | - |
Other Long-Term Liabilities | 169.52 | 603.1 | 651.48 | 709.36 | 448.55 |
Total Liabilities | 1,545 | 1,577 | 1,659 | 1,649 | 1,051 |
Common Stock | 446.9 | 399.4 | 399.4 | 399.4 | 374.93 |
Additional Paid-In Capital | 3,345 | 2,218 | 1,992 | 1,992 | 1,516 |
Retained Earnings | -1,573 | -1,754 | -1,787 | -1,404 | -802.32 |
Treasury Stock | -45.35 | -32.76 | -27.18 | -18.99 | - |
Comprehensive Income & Other | 1.33 | 2.69 | 209.09 | 178.32 | 159.03 |
Total Common Equity | 2,175 | 834.06 | 785.89 | 1,146 | 1,247 |
Minority Interest | 4.54 | 4.55 | 4.55 | 4.55 | 4.76 |
Shareholders' Equity | 2,179 | 838.6 | 790.44 | 1,151 | 1,252 |
Total Liabilities & Equity | 3,724 | 2,415 | 2,449 | 2,800 | 2,303 |
Total Debt | 584.09 | 570.28 | 544.11 | 415.28 | 89.8 |
Net Cash (Debt) | 1,001 | -166.43 | -110.07 | 228.69 | 483.62 |
Net Cash Growth | - | - | - | -52.71% | -44.82% |
Net Cash Per Share | 2.49 | -0.40 | -0.28 | 0.60 | 1.33 |
Filing Date Shares Outstanding | 446.9 | 399.4 | 399.4 | 399.4 | 396.69 |
Total Common Shares Outstanding | 446.9 | 399.4 | 399.4 | 399.4 | 374.93 |
Working Capital | 1,218 | 281.62 | 145.43 | 313.25 | 427.68 |
Book Value Per Share | 4.87 | 2.09 | 1.97 | 2.87 | 3.33 |
Tangible Book Value | 2,122 | 772.92 | 757.76 | 1,116 | 1,241 |
Tangible Book Value Per Share | 4.75 | 1.94 | 1.90 | 2.79 | 3.31 |
Buildings | 1,057 | 1,057 | - | - | - |
Machinery | 506.04 | 442.16 | 1,437 | 1,208 | 1,107 |
Construction In Progress | 34.09 | 1.73 | 5.19 | 268.29 | 181.96 |
Leasehold Improvements | - | - | 240.53 | 161.75 | 166.43 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.